Puma Biotechnology (0PB) Q2 2026 Earnings Report

The call highlights strong commercial momentum: meaningful QoQ and YoY increases in NERLYNX demand and bottle sales, a return to GAAP profitability in Q2, raised full-year revenue and net income guidance, and elimination of debt. These positives are tempered by pressure from high gross-to-net deductions (~28%), potential royalty reductions in China when generics gain share, rising R&D spend and increased quarter-over-quarter cash burn, and operational items like elevated DSO and a QoQ decline in new patient starts. On balance, the company appears to be in a strengthening commercial and financial position while managing identifiable near-term risks tied to deductions, international royalties, and increased investment in clinical programs.

Puma updated 2026 guidance, raising net NERLYNX product revenue to $205–$209 million (up from prior $202–$206M), with a full‑year gross‑to‑net of 26.5%–27.5%, expected royalties of $19–$22 million (versus prior $20–$23M), and projected full‑year net income of $17–$20 million (versus prior $16–$19M); the company does not expect any license revenue in 2026 and will continue to record amortization/milestone expense of about $2.4 million per quarter as cost of sales. For Q3 2026 Puma guided net product revenue of $54–$56 million, royalties of $2–$3 million, a Q3 gross‑to‑net of roughly 26%–27%, and Q3 net income of $2.0–$2.5 million. Management also cautioned that the China sublicense contains a generics‑triggered royalty reduction that could occur in late 2026 or 2027 and noted the company is debt‑free with approximately $93.9 million in cash, cash equivalents and marketable securities at June 30, 2026.